Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Zyversa Therapeutics Inc (ZVSA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Zyversa Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.4500 -0.2900    -5.05%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
5.4100
-0.0400
-0.7339%
19:55:34 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 374,652
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 5.2501 - 6.0000
Zyversa Therapeutics 5.4500 -0.2900 -5.05%

Zyversa Therapeutics Inc Company Profile

 
Get an in-depth profile of Zyversa Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

7

Equity Type

ORD

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

Contact Information

Address 2200 N. Commerce Parkway Suite 208
Weston, 33326
United States
Phone 754 231 1688
Fax -

Top Executives

Name Age Since Title
Sharon G. Adler - - Member of Scientific Advisory Board
Stephen C. Glover 63 2022 Co-Founder, Chairman, CEO & President
Pablo A. Guzman 73 2023 Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board
Min-Chul Park 41 2022 Independent Director
Robert W. Keane - - Member of Scientific Advisory Board
Douglas H. Farrar 58 - Member of Scientific Advisory Board
Alan C. Herman 75 - Member of Scientific Advisory Board
William F. Bennett 74 - Member of Scientific Advisory Board
Robert G. Finizio 52 2022 Independent Director
Miguel S. Barbosa 65 - Member of Scientific Advisory Board
Marlene Haffner 82 - Member of Scientific Advisory Board
Fernando C. Fervenza - - Member of Renal Scientific Advisory Board
W. Dalton Dietrich 70 - Member of Scientific Advisory Board
Daniel G. Baker - - Member of Scientific Advisory Board
James R. Sapirstein 62 2023 Independent Director
Gregory G. Freitag 61 2023 Independent Director
Nicholas A. LaBella 67 2022 Member of Scientific Advisory Board
Juan Pablo de Rivero Vaccari - - Member of Scientific Advisory Board
Alessia Fornoni - - Member of Scientific Advisory Board
Helen Bramlett - - Member of Scientific Advisory Board
Daniel C. Cattran - - Member of Renal Scientific Advisory Board
Richard J. Glassock - 2023 Member of Renal Scientific Advisory Board
Douglas T. Golenbock - 2023 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ZVSA Comments

Write your thoughts about Zyversa Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oamr Soliman
Oamr Soliman Nov 29, 2023 4:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I see 7 dollars before christmas
Nhat Doan
Nhat Doan Dec 15, 2022 3:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
∆ SYMBOLS that can not be SHORT Must not BUY and DELETE Forever. 🤗🤩👍👹💣∆
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email